One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status.
Harper, Diane M. MD, MPH, MS 1,
doi : 10.1200/JCO.22.00609
Volume 40(26) pgs. 3003-3098 September 10, 2022
Leveraging Circulating Tumor DNA to Optimize the Initial Management of Childhood Renal Tumors.
Ortiz, Michael V. MD 1,
doi : 10.1200/JCO.22.00820
Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?.
Hussain, Maha MD 1,; Carducci, Michael A. MD 2; Clarke, Noel MBBS 3; Fenton, Sarah E. MD, PhD 1; Fizazi, Karim MD, PhD 4; Gillessen, Silke MD, PhD 5,6,7; Jacene, Heather MD 8; Morris, Michael J. MD 9; Saad, Fred MD 10; Sartor, Oliver MD 11; Taplin, Mary-Ellen MD 12; Vapiwala, Neha MD 13; Williams, Scott MD 14; Sweeney, Christopher MD 12
doi : 10.1200/JCO.22.00208
With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
Madan, Ravi A. MD 1,; Mena, Esther MD 2; Lindenberg, Liza MD 2; Choyke, Peter L. MD 2
doi : 10.1200/JCO.22.00493
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang, Andres MD, PhD 1,2; Akhtar, Akil PhD 2; Linderman, Susanne L. PhD 2; Lai, Lilin MD 2,3,4; Orellana-Noia, Victor M. MD 1; Valanparambil, Rajesh PhD 2; Ahmed, Hasan MPH 2,5; Zarnitsyna, Veronika I. PhD 2,5; McCook-Veal, Ashley A. MPH 6; Switchenko, Jeffrey M. PhD 6; Koff, Jean L. MD 1; Blum, Kristie A. MD 1; Ayers, Amy A. MPH 1,7; O'Leary, Colin B. MA 1; Churnetski, Michael C. BSc 1; Sulaiman, Shahana MD 1; Kives, Melissa MPH 1; Sheng, Preston BSc 2; Davis, Carl W. MD, PhD 2; Nooka, Ajay K. MD 1; Antia, Rustom PhD 2,5; Dhodapkar, Madhav V. MD 1; Suthar, Mehul S. PhD 2,3; Cohen, Jonathon B. MD 1; Ahmed, Rafi PhD 2,
doi : 10.1200/JCO.22.00088
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju, Naveen MD 1,; Sweet, Kendra L. MD 2; Stein, Anthony S. MD 3; Wang, Eunice S. MD 4; Rizzieri, David A. MD 5; Vasu, Sumithira MD, MBBS 6; Rosenblat, Todd L. MD 7; Brooks, Christopher L. PhD 8; Habboubi, Nassir PhD 8; Mughal, Tariq I. MD 8,9; Kantarjian, Hagop MD 1; Konopleva, Marina MD, PhD 1; Lane, Andrew A. MD, PhD 10
doi : 10.1200/JCO.22.00034
Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4/miR124-2 DNA Methylation (CONCERVE Study).
Kremer, Wieke W. PhD 1; Dick, Stefanie MSc 1; Heideman, Danielle A.M. PhD 1; Steenbergen, Renske D.M. PhD 1; Bleeker, Maaike C.G. PhD 1; Verhoeve, Harold R. PhD 2; van Baal, W. Marchien PhD 3; van Trommel, Nienke PhD 4; Kenter, Gemma G. PhD 5; Meijer, Chris J.L.M. PhD 1; Berkhof, Johannes PhD 6,
doi : 10.1200/JCO.21.02433
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
Madanat-Harjuoja, Laura M. MD, PhD 1; Renfro, Lindsay A. PhD 2; Klega, Kelly MS 1; Tornwall, Brett PhD 3; Thorner, Aaron R. PhD 4; Nag, Anwesha PhD 4; Dix, David MD 5; Dome, Jeffrey S. MD, PhD 6; Diller, Lisa R. MD 1; Fernandez, Conrad V. MD 7; Mullen, Elizabeth A. MD 1; Crompton, Brian D. MD 1,8,
doi : 10.1200/JCO.22.00098
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
Nooka, Ajay K. MD 1,2; Shanmugasundaram, Uma PhD 1; Cheedarla, Narayana PhD 3; Verkerke, Hans BS 3; Edara, Venkata V. PhD 4,5; Valanparambil, Rajesh PhD 4,5; Kaufman, Jonathan L. MD 1,2; Hofmeister, Craig C. MD 1,2; Joseph, Nisha S. MD 1,2; Lonial, Sagar MD 1,2; Azeem, Maryam BS 1; Manalo, Julia BS 1; Switchenko, Jeffrey M. PhD 2; Chang, Andres MD 1,2; Linderman, Susanne L. PhD 4; Roback, John D. MD 2,3; Dhodapkar, Kavita M. MD 2,6; Ahmed, Rafi PhD 2,4; Suthar, Mehul S. PhD 4,5,7; Neish, Andrew S. MD 2,3; Dhodapkar, Madhav V. MD 1,2,
doi : 10.1200/JCO.21.02257
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen, Lin MD, PhD 1,; Kato, Ken MD, PhD 2; Kim, Sung-Bae MD, PhD 3; Ajani, Jaffer A. MD, PhD 4; Zhao, Kuaile MD 5; He, Zhiyong MD 6; Yu, Xinmin MD 7; Shu, Yongqian MD 8; Luo, Qi MD 9; Wang, Jufeng MD, PhD 10; Chen, Zhendong MD 11; Niu, Zuoxing MD 12; Zhang, Longzhen MD 13; Yi, Tienan MD 14; Sun, Jong-Mu MD, PhD 15; Chen, Jianhua MD, PhD 16; Yu, Guohua MD 17; Lin, Chen-Yuan MD, PhD 18; Hara, Hiroki MD 19; Bi, Qing MD 20; Satoh, Taroh MD 21; Pazo-Cid, Roberto MD 22; Arkenau, Hendrick-Tobias MD, PhD 23; Borg, Christophe MD, PhD 24; Lordick, Florian MD, PhD 25; Li, Liyun MD 26; Ding, Ningning MD 26; Tao, Aiyang PhD 26; Shi, Jingwen PhD 26; Van Cutsem, Eric MD, PhD 27; for the RATIONALE-302 Investigators
doi : 10.1200/JCO.21.01926
Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.
Timmerman, Dennis M. MSc 1; Eleveld, Thomas F. PhD 1; Sriram, Sruthi MSc 1; Dorssers, Lambert C.J. PhD 2; Gillis, Ad J.M. Ing 1; Schmidtova, Silvia PhD 3,4; Kalavska, Katarina Ing 3,4,5; van de Werken, Harmen J.G. PhD 6; Oing, Christoph MD, PhD 7,8; Honecker, Friedemann MD, PhD 7,9; Mego, Michal MD, PhD 3,4,5; Looijenga, Leendert H.J. PhD 1,
doi : 10.1200/JCO.21.02809
Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
Moy, Beverly MD, MPH 1,; Rumble, R. Bryan MSc 2; Carey, Lisa A. MD, ScM 3,; for the Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor-Negative Expert Panel
doi : 10.1200/JCO.22.01533
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.
Zeng, Shuxiong MD, PhD; Zhang, Zhensheng MD, PhD; Xu, Chuanliang MD, PhD
doi : 10.1200/JCO.22.00669
Reply to S. Zeng et al.
Pfister, Christian MD, PhD; Harter, Valentin MSc; Allory, Yves MD, PhD; Culine, Stephane MD, PhD; for the VESPER Trial Investigators
doi : 10.1200/JCO.22.01031
Change in Pattern of Failure in Head and Neck Cancer.
Noronha, Vanita MBBS, MD, DM; Patil, Vijay Maruti MBBS, MD, DM; Menon, Nandini MBBS, MD, DNB; Prabhash, Kumar MBBS, MD, DM
doi : 10.1200/JCO.22.00598
